...
首页> 外文期刊>Cardiovascular Diabetology >Impact of CD14 ++ CD16 + monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study
【24h】

Impact of CD14 ++ CD16 + monocytes on plaque vulnerability in diabetic and non-diabetic patients with asymptomatic coronary artery disease: a cross-sectional study

机译:CD14 ++ CD16 +单核细胞对无症状冠状动脉疾病糖尿病和非糖尿病患者斑块脆弱性的影响:横截面研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Previously, we have reported that daily glucose fluctuations could affect coronary plaque vulnerability, but the underlying mechanisms remained unclear. This study sought to investigate the impact of CD14++CD16+ monocytes on plaque vulnerability, as assessed by virtual histology intravascular ultrasound (VH-IVUS), as well as their relationship to fluctuating glucose levels in patients with asymptomatic coronary artery disease (CAD). Methods Fifty-one patients with asymptomatic CAD, who were undergoing lipid-lowering therapy and underwent VH-IVUS evaluation for angiographically mild to moderate lesions, were enrolled in the study. Standard VH-IVUS parameters, including the percentage volume of the necrotic core (%NC) within the plaque and the presence of a virtual histology thin-cap fibroatheroma (VH-TCFA), were then evaluated. Additionally, monocyte subsets were assessed by flow cytometry, and daily glucose fluctuations were analyzed by measuring the mean amplitude of glycemic excursion (MAGE). Results Among 82 plaques from 22 diabetes mellitus (DM) patients and 29 non-DM patients, 15 VH-TCFAs were identified. CD14++CD16+ monocyte counts significantly correlated with both %NC and the presence of VH-TCFA (%NC: r?=?0.339, p?=?0.002; VH-TCFA: p?=?0.003). Multivariate logistic regression analysis revealed that CD14++CD16+ monocyte counts were independently associated with VH-TCFA (odds ratio?=?1.029, p?=?0.004). Furthermore, CD14++CD16+ monocyte counts were significantly correlated with the MAGE score in the non-DM patients (r?=?0.544, p?=?0.005). Conclusions CD14++CD16+ monocyte levels are associated with coronary plaque vulnerability and can serve as a biomarker for VH-TCFA in patients with CAD undergoing lipid-lowering therapy. In patients without DM, glucose fluctuations may alter the balance of monocyte subsets. Trial registration UMIN Registry number: UMIN000021228
机译:背景技术先前,我们报告说,日常葡萄糖波动可能影响冠状动脉斑块脆弱性,但潜在机制仍然不清楚。该研究寻求研究CD14 ++ cd16 + 单核细胞对斑块脆弱性的影响,如虚拟组织学血管内超声(Vh-IVUS)的评估,以及它们的关系对无症状冠状动脉疾病患者(CAD)的波动水平波动。方法研究脂质降低治疗的五十一患者,患有降脂治疗和血管造影缓解至中等病灶的VH-IVUS评估,均注册研究。然后评估标准VH-IVUS参数,包括斑块内的坏死核心(%NC)的百分比(%NC)和存在虚拟组织学薄帽纤维瘤(VH-TCFA)。另外,通过流式细胞术评估单核细胞子集,通过测量血糖偏移的平均振幅(法师)进行日常血糖波动。结果22例糖尿病(DM)患者的82个斑块中,鉴定了15例VH-TCFA。 CD14 ++ cd16 + 单核细胞计数与%nc和vh-tcfa的存在显着相关(%nc:r?= 0.339,p?= 0.002; VH-TCFA:P?= 0.003)。多变量逻辑回归分析显示CD14 ++ cd16 + 单核细胞计数与Vh-tcfa(odds比Δ=Δ=Δ1.029,p?= 0.004)独立相关。此外,CD14 ++ cd16 + 单核细胞计数与非DM患者的法师分数显着相关(r?= 0.544,p?= 0.005)。结论CD14 ++ CD16 + 单核细胞水平与冠状动脉斑块脆弱性有关,可以作为CAD患者进行脂质降低治疗的患者VH-TCFA的生物标志物。在没有DM的患者中,葡萄糖波动可能会改变单核细胞子集的平衡。试用登记UMIN注册表号:UMIN000021228

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号